argenex SE (NASDAQ:ARGX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus is “Moderate Buy”: Of 24 analysts covering argenx, 17 recommend buying, two recommend a strong buy, and five rate it a hold. The average 12-month price target is $1,158.61.
• argenx reported quarterly EPS of $7.32, beating estimates of $5.86, while revenue reached $1.54 billion versus the $1.45 billion consensus forecast.
• Institutional ownership stands at 60.32%, with several major funds—including Sands Capital, Invesco and Wellington Management—recently increasing their positions.

argenex SE (NASDAQ:ARGX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-four analysts that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $1,158.6111.

ARGX has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft downgraded argenex from a "buy" rating to a "hold" rating in a report on Monday, August 24th. Weiss Ratings downgraded argenex from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, July 23rd. Citizens Jmp upped their target price on shares of argenex from $932.00 to $1,200.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 18th. Morgan Stanley raised their target price on shares of argenex from $1,230.00 to $1,250.00 and gave the company an "overweight" rating in a report on Monday, August 31st. Finally, Truist Financial raised their target price on shares of argenex from $1,030.00 to $1,095.00 and gave the company a "buy" rating in a report on Tuesday, August 18th.

argenex Stock Down 2.5%

Shares of ARGX opened at $1,007.07 on Wednesday. The company has a market cap of $63.00 billion, a P/E ratio of 38.67, a PEG ratio of 1.07 and a beta of 0.47. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The firm's 50 day moving average price is $930.46 and its 200 day moving average price is $844.09.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion during the quarter, compared to analysts' expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. Research analysts forecast that argenex will post 29.13 earnings per share for the current year.

Institutional Investors Weigh In On argenex

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Sands Capital Management LLC lifted its holdings in argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company's stock worth $300,110,000 after buying an additional 340,245 shares during the last quarter. Invesco Ltd. boosted its position in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company's stock worth $350,178,000 after acquiring an additional 331,489 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company's stock valued at $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company's stock valued at $216,961,000 after acquiring an additional 250,278 shares during the last quarter. Finally, Corient Private Wealth LLC raised its position in shares of argenex by 12,441.8% during the 4th quarter. Corient Private Wealth LLC now owns 246,572 shares of the company's stock worth $207,355,000 after acquiring an additional 244,606 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Company Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.